ribosomal protein L7a pseudogene 65Genealiases: []
Q-omics provides the consensus-scored RPL7AP65 profile across patient tissues and cancer cell-line models. RPL7AP65 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RPL7AP65 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, RPL7AP65 RNA expression shows 12,486 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UVM, COAD, and GBM as cancer lineages where RPL7AP65 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL7AP65 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL7AP65 survival associations across molecular data types. RPL7AP65 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL7AP65 RNA expression–survival associations across cancer types. High RPL7AP65 expression shows unfavorable associations in UVM, ACC, KIRC, THYM and UCEC, but favorable associations in LUAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RPL7AP65 RNA expression.
This table summarizes RPL7AP65 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL7AP65. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL7AP65 shows higher tumor expression in COAD, LUSC, HNSC, BRCA, STAD and BLCA. The COAD box plot shows higher RPL7AP65 RNA expression in tumor versus normal tissue (log2 FC = +0.240, t-test p = .001).
This table shows molecular features associated with RPL7AP65 in patient tissues and cancer cell lines. In patient samples, RPL7AP65 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
